Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Vainchtein

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Pharmaceutics|October 3, 2006
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studiesS C van der Schoot, L D Vainchtein, J H Beijnen, et al.
Die Pharmazie|December 17, 2008
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrinS C van der Schoot, L D Vainchtein, B Nuijen, et al.
Investigational New Drugs|May 1, 2009
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumorsR L Oostendorp, P O Witteveen, B Schwartz, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2011
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabineM Joerger, J A Burgers, P Baas, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 14, 2006
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout miceM L H Vlaming, K Mohrmann, E Wagenaar, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Pharmaceutics|October 3, 2006
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studiesS C van der Schoot, L D Vainchtein, J H Beijnen, et al.
Die Pharmazie|December 17, 2008
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrinS C van der Schoot, L D Vainchtein, B Nuijen, et al.
Investigational New Drugs|May 1, 2009
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumorsR L Oostendorp, P O Witteveen, B Schwartz, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2011
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabineM Joerger, J A Burgers, P Baas, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 14, 2006
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout miceM L H Vlaming, K Mohrmann, E Wagenaar, et al.
Pageof 1